BLA 103608 · Cytogen
Prostascint
Capromab Pendetide · Intravenous
NovelPriority reviewLast checked: Nov 20, 2026Latest source record: Jun 26, 2012 (newest FDA action)Source: Drugs@FDA, openFDA, CMS, ClinicalTrials.gov, PubMedMethods & limitations
First approved
1996
Oct 28, 1996
Approved uses
1
Original approval plus efficacy supplements
Registered trials
2
0 Phase 3, 0 recruiting
FAERS reports
0
0 serious, 0 with death reported
AI brief across all sources
Written by AI from the FDA, CMS, ClinicalTrials.gov, FAERS and PubMed data on this page, plus web searches for pricing, exclusivity and pending FDA decisions.
What it is approved for
No structured label for this application in openFDA. Older and discontinued products often have none.
Approval history
Original approval and efficacy supplements (new uses, populations or doses), newest first, with FDA's letters and labels.
1 products under this application
- PROSTASCINT · CAPROMAB PENDETIDE 05.MG/ML · VIAL, INTRAVENOUS · Prescription
Clinical trials
Interventional ClinicalTrials.gov studies with "Capromab Pendetide" as an intervention, any sponsor and status, largest first.
David M. Schuster, MDAcademic, hospital or other
NCT00562315 · 128 participants · Start Oct 2007 · Primary completion Jul 2015
Drug: FACBC · For: Prostate Cancer
Sites: Atlanta, Georgia
Molecular Insight Pharmaceuticals, Inc.Industry
NCT00992745 · 24 participants (planned) · Start Oct 2009 · Primary completion Sep 2011
Drug: 123-I-MIP-1072; 111-In capromab pendetide and 1 more · For: Prostate Cancer
Sites: Laguna Niguel, California; Newport Beach, California; San Francisco, California · 7 sites in all
Most reported adverse reactions
FAERS reports naming this application or brand. Unverified reports, not rates; a report can name several drugs.
No FAERS reports name this application.
FAERS reports by year
By the date FDA received the report.
No reports.
Recalls
0 FDA enforcement reports for this application.
No recalls on record for this application.
Shortages
FDA's drug shortage list.
Not on FDA's shortage list.
Medicare spending
CMS Spending by Drug. Part D is pharmacy-dispensed; Part B is given in a clinic or hospital outpatient setting. Spending is before manufacturer rebates.
Not found under this brand name in Medicare's Part D or Part B Spending by Drug data. CMS lists some drugs under the generic name only.
Published evidence
PubMed clinical trials, meta-analyses and systematic reviews, most relevant first.
- Multicenter radioimmunoscintigraphic evaluation of patients with prostate carcinoma using indium-111 capromab pendetide.
Hinkle GH, Burgers JK, Neal CE, et al. · Cancer 1998 · Clinical Trial, Clinical Trial, Phase III
- The value of anti-1-amino-3-18F-fluorocyclobutane-1-carboxylic acid PET/CT in the diagnosis of recurrent prostate carcinoma: a meta-analysis.
Ren J, Yuan L, Wen G, et al. · Acta Radiol 2016 · Meta-Analysis, Research Support, Non-U.S. Gov't
- A systematic review of the role of imaging before salvage radiotherapy for post-prostatectomy biochemical recurrence.
Beresford MJ, Gillatt D, Benson RJ, et al. · Clin Oncol (R Coll Radiol) 2010 · Systematic Review
- Evaluation of preoperative ProstaScint scans in the prediction of nodal disease.
Ponsky LE, Cherullo EE, Starkey R, et al. · Prostate Cancer Prostatic Dis 2002 · Clinical Trial
- Immunoscintigraphy with indium-111-capromab pendetide: evaluation before definitive therapy in patients with prostate cancer.
Manyak MJ, Hinkle GH, Olsen JO, et al. · Urology 1999 · Clinical Trial, Research Support, Non-U.S. Gov't
- Evaluation of phase I/II clinical trials in prostate cancer with dendritic cells and PSMA peptides.
Tjoa BA, Simmons SJ, Bowes VA, et al. · Prostate 1998 · Clinical Trial, Clinical Trial, Phase I
Sponsor: Cytogen
For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.